Repligen (RGEN)

• Market cap: $6.99B
• 1 day: -2.38%
• 5 days: 0.55%
• 1 month: -5.51%
• 3 months: 7.17%
• 6 months: -18.94%
• Year to date: -13.02%
• 1 year: 3.87%
• 5 years: 0.23%
• 10 years: 195.28%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Employees: 1,778

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

38% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 45

29% more repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 130

2% more funds holding

Funds holding: 429 [Q4 2024] → 439 (+10) [Q1 2025]

1.43% more ownership

Funds ownership: 100.37% [Q4 2024] → 101.8% (+1.43%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

10% less capital invested

Capital invested by funds: $8.09B [Q4 2024] → $7.31B (-$782M) [Q1 2025]

84% less call options, than puts

Call options by funds: $11M | Put options by funds: $68.6M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $150 21% upside
• Avg. target: $172 38% upside
• High target: $190 53% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Barclays Luke Sergott	21% upside $150	Overweight Initiated	24 Jun 2025
HC Wainwright & Co. Raghuram Selvaraju	45% upside $180	Buy Reiterated	5 May 2025
RBC Capital Conor McNamara	52% upside $189	Outperform Maintained	30 Apr 2025
JP Morgan Rachel Vatnsdal	53% upside $190	Overweight Maintained	29 Apr 2025
Canaccord Genuity Kyle Mikson	21% upside $150	Hold Maintained	16 Apr 2025